Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database
- Authors
- Choi, Jung Yoon; Cho, Eun Young; Choi, Yoon Ji; Lee, Jeong Hyeon; Jung, Seung Pil; Cho, Kyu Ran; Kim, Chul Yong; Kim, Yeul Hong; Park, Kyong Hwa
- Issue Date
- Aug-2018
- Publisher
- SPRINGER
- Keywords
- Congestive heart failure; Anthracycline; Trastuzumab; Breast cancer
- Citation
- BREAST CANCER RESEARCH AND TREATMENT, v.171, no.1, pp 181 - 188
- Pages
- 8
- Indexed
- SCI
SCIE
SCOPUS
- Journal Title
- BREAST CANCER RESEARCH AND TREATMENT
- Volume
- 171
- Number
- 1
- Start Page
- 181
- End Page
- 188
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/3304
- DOI
- 10.1007/s10549-018-4809-8
- ISSN
- 0167-6806
1573-7217
- Abstract
- We aimed to analyze the incidence, time to occurrence, and congestive heart failure (CHF) risk factors for early breast cancer patients treated with anthracycline (AC)-based chemotherapy and/or trastuzumab (T) therapy in Korea. We included female patients > 19 years old from the Health Insurance Review and Assessment Service database who had no prior CHF history and had been diagnosed with early breast cancer between January 2007 and October 2016. We included 83,544 patients in our analysis. In terms of crude incidence for CHF, AC followed by T showed the highest incidence (6.3%). However, 3.1 and 4.2% of the patients had CHF due to AC-based chemotherapy and non-AC followed by T, respectively. The median times to occurrence of CHF were different according to adjuvant treatments, approximately 2 years (701.0 days) in the AC-based chemotherapy group vs 1 year (377.5 days) AC followed by T group. T therapy was associated with earlier development of CHF irrespective of previous chemotherapy, but late risk of CHF 1.2 years after T therapy rapidly decreased in both chemotherapy groups. Multivariate Cox regression analysis revealed that the adjusted hazard ratio for CHF was increased in the group of older patients ( 65 years old) who underwent AC followed by T therapy, with Charlson comorbidity index scores of 2. Our study showed that neo-/adjuvant chemotherapy using T irrespective of previous chemotherapy (AC or non-AC) was associated with significantly increased risk of CHF compared with AC-based chemotherapy in Korean patients with early breast cancer.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Radiation Oncology > 1. Journal Articles
- 2. Clinical Science > Department of Radiology > 1. Journal Articles
- 2. Clinical Science > Department of Anesthesiology and Pain Medicine > 1. Journal Articles
- 2. Clinical Science > Department of Pathology > 1. Journal Articles
- 2. Clinical Science > Department of Medical Oncology and Hematology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.